1. ACED PILOT AWARD GUIDANCE for Understanding Disease Progression for Early Detection Call 2021/2022

ACED Pilot Awards fund exceptional science, supporting innovative, novel approaches in understanding cancer progression through collaborative research with ACED Members.

Submit completed applications to your local Programme Manager (Section 3: Useful Contacts) in Word format.

1.1. SUMMARY OF AWARD

Amount: up to £200,000 (approx. $250,000) total award across Member Centres

Eligibility: Applicants must be named Alliance Members of one of the following institutions: Canary Center at Stanford University, the University of Cambridge, the OHSU Knight Cancer Institute, University College London or The University of Manchester. Please check with your local ACED Programme Manager to ensure you are a named Alliance Member for your institution before applying.

Scope: The proposal must be within scope of Understanding Disease Progression for Early Detection as defined in Section 1.2 of this guidance document.

Project duration: up to 12 months

Restrictions: Each proposal must include joint lead applicants from at least two Alliance Member Centres. Collaboration between US and UK Member Centres is encouraged, but not mandatory. You must receive signatory approval from the submitting Member Centre Director, and the appropriate Centre approvers, for your application.

Please submit ONE application for each Pilot proposal; lead applicants can determine which Alliance Member Centre to submit their application through.

1.2. REMIT OF THE ACED PILOT AWARD 2021/2022

The ACED Executive Board invites proposals for innovative early-stage collaborative research which explores the following question: Can the early detection of cancer be informed by an improved understanding of disease progression from early pre-malignant changes to consequential cancer?

This award provides up to one year of seed funding of up to £200,000 (approx. $250,000) to support new and pioneering research ideas and/or pilot studies of high scientific risk, allowing the development of new partnerships and exploration of highly novel concepts. We envisage that data generated, or collaborations established through an ACED Pilot Award will form the basis for a more extensive subsequent early detection research project. There is no requirement for extensive preliminary data to support your application (although any data you do have will be considered). A clear hypothesis to address an unmet need in the field is essential.

The Challenge: One of the great challenges in cancer early detection research is understanding and predicting progression across the continuum of malignant transformation at every stage of the disease. Clinical cancer screening approaches are becoming more available than ever before, and the
The predictive accuracy of risk stratification tools continues to improve – now, more than ever, it is essential to stratify risk and predict disease progression toward lethality once an early lesion is detected. For example, breast screening identifies individuals at elevated risk of cancer (e.g. high-density breasts) and with early non-invasive lesions (e.g. DCIS). Lung screening does likewise (e.g. ground glass opacities and indeterminate nodules). For these existing tests, there is an unmet clinical need to be able to predict which lesions are likely to progress (and so may require more aggressive strategies; this need will only grow as other screening technologies are developed. This prognostic ability will be crucial in tailoring future monitoring, early detection or interventional strategies, in order to maximise patient benefit and minimise potential harm through over-treatment or unnecessary invasive follow up.

**Addressing the clinical challenge to assess the risk of cancer progression in individuals with detected early lesions from normal/at-risk to dysregulated to pre-cancerous to malignancy is essential to best tailor early detection strategies, monitoring and preventative interventions.**

**The Opportunity:** The ACED Executive Board (AEB) have identified this challenge - **Understanding Disease Progression for Early Detection** - as a key strategic theme for the Alliance. This view was consolidated by the ACED Scientific Advisory Board (SAB) and through consultation with the wider ACED community through a recent crowd-sourcing process for open submission of “Big Ideas”.

The AEB wish to support highly collaborative research pilot projects into **Understanding Disease Progression for Early Detection.** Within the context of this challenge area, the exact nature of proposals is open to investigator-driven ideas. Example research questions (derived from the ACED community and SAB) include:

- Individuals with high germline genomic risk can exist for a long time without cancer, and then suddenly develop one - what triggered it? Are there key insults which trigger progression to cancer in those at high risk: immune dysfunction, physical trauma, infection?
- What are the factors and redundancies that prevent at-risk individuals from progressing? Might understanding those factors give us information that can predict low risk of progression in at-risk individuals or those with early changes?
- Can serial, longitudinal samples from cohorts of individuals provide key signals predictive of progression from healthy to early changes to invasive cancer? Can existing sample collections be harnessed to provide such insights?
- Can studying dormancy and progression to relapse provide information which gives insight into primary progression towards invasive disease?
- Can the latent stage of early lesions (when suppressor mechanisms are active) be mapped, so giving us insight into risk of progression?
- Can we understand the environmental context of the early lesion, and what changes subsequently allow it to grow/progress?
- Can the study of phenotypically normal tissue carrying what would appear to be driver mutations, compared to early and established cancers, give us insight into what drives progression?
- Are there signals in the spatial heterogeneity of phenotypically normal, premalignant and malignant tissue which predict progression?
- Can study of risk mutation carriers with and without cancer and non-carriers in the same families allow characterization of differences in germline, pre-cancerous lesion or tumour to give prognostic insight?
It is anticipated that successful proposals to this call will be highly collaborative across ACED Centres and will involve team members from multiple scientific disciplines, including but not limited to examples such as:

- Methodological development
- Statistics
- Epidemiology and risk stratification
- Genomics
- Molecular, Cell and tissue biology
- Model systems
- Biomarker discovery
- Pathology and imaging
- Technology development
- Mathematical modelling
- Clinical trials
- Oncology and medical genetics
- Cohorts and biosample collections

1.3. ELIGIBILITY

Host institution approval
To be eligible, the joint lead applicants on the Award must be named Alliance members at the following institutions: Canary Center at Stanford University, University of Cambridge, OHSU Knight Cancer Institute, University College London or The University of Manchester. Additional collaborators outside these institutions should be named in the ‘Collaborative team’ section of the application, clearly articulating the gaps in expertise that these collaborators provide that is not currently available within the Alliance. Collaborative Partners external to ACED must be deemed ‘Affiliate Members’ by your host institution. These external collaborators are not eligible for ACED funding (e.g. cannot receive funds directly from CRUK but can receive funds form Alliance Member Centres if deemed reasonable and justified). Due to specific considerations regarding data generation and sharing, you must discuss with your ACED local Programme Manager in the first instance prior to completing your application if you are planning to include Affiliate Members.

Your Member Centre Director must approve your application before you have submitted it, so please submit your completed application to your local ACED Programme Manager (Section 3: Useful contacts) before the indicated deadline. Your proposal should also comply with all appropriate local regulatory, ethical and research governance procedures.

Applications to other funding bodies
If you are applying to other funding bodies at the same time, please note that we cannot accept the same application. If you submit an application to the Alliance that is already being considered by another funding body, your application will not be accepted.

1.3. WHAT IS FUNDED?

The Award can fund pilot experiments and associated running costs (including lab consumables, data storage/exchange costs, minor equipment, facility access charges etc.). Funds may also be used to cover the cost of travel and meeting organisation between collaborators named on your application.

For the ACED Pilot Award, you may request salary support for research staff employed specifically to work on the grant (including technicians, but not administrative support).
If you are a UK-based lead applicant, joint lead applicant or co-investigator, you may only apply for costs to cover your own salary if you are an early- to mid-career researcher (as defined by the Develop Independence or Establish Independence career stage of CRUK’s Competency Framework) and you also:

a) meet all the criteria laid out in the Policy on Salaries of Investigators; and
b) can justify how the salary would support a significant career transition towards independence.

If you are an OHSU lead applicant, you must include your salary costs if you are CEDAR staff, if your home Centre is not CEDAR, you may or may not include salary costs as needed. For applications involving the Stanford Canary, a Centre full member must be included as part of the application, full list available here: https://canarycenter.stanford.edu/people/full-members.html

In general, funds requested from both US and UK applicants should be directed towards direct research costs.

1.4. ASSESSMENT CRITERIA

The Alliance Executive Board will judge your proposal on:

- **Relevance to Alliance scientific strategy and remit**: All applications must be within scope of the Understanding Disease Progression for Early Detection 2021/2022 call as outlined in Section 1.2 of this guidance document.
- **Scientific excellence, novelty and risk**: All applications must have a strong scientific rationale to support the proposed research proposal, robust experimental design and include novel and innovative approaches. High scientific risk/high reward approaches are encouraged.
- **The challenge addressed**: what is the unmet research and/or clinical need which the proposal would address? How would knowledge be advanced to meet that need?
- **Line of sight to clinical/population impact**: The proposed work must have the potential for a remarkable impact on cancer detection. Whilst not all applications will be translational in nature, it is important that all research is designed with a clear line of sight to clinical/population impact and the proposal should clearly articulate this pathway and the evidence and outputs that will be required to advance along it. Appropriate consultation/collaboration with clinicians, population scientists, industrial partners, patients and/or the public should be included to facilitate this.
- **Excellent team and collaborative environment**: All applications should outline the suitability and feasibility of the lead applicants (and supporting roles) to carry out the proposed research with access to the resources and facilities required for the successful fulfilment of the award. Applications should highlight the importance of the Alliance environment in supporting the potential of the proposed research and address how Alliance partnerships will uniquely enable the proposed research compared to Alliance Member Centres conducting the research independently. Multidisciplinary, transatlantic collaboration is encouraged when appropriate to the science proposed. It is important to demonstrate the added value of the proposed collaboration and the individual contributions, as well as the steps taken to ensure an effective collaboration.
- **Resources requested**: The costs requested in an application should be for the direct costs of the research only and reasonably justified in line with the experimental plans, leveraging existing resources where appropriate.
• **Benefit to the wider Alliance:** Applications should detail the actual and potential benefits to the wider Alliance community, including any infrastructural benefits, knowledge exchange, data sharing, etc.

2. **THE APPLICATION PROCESS**

2.1 **PROCESS OVERVIEW**

Complete the provided template and submit your application to your local ACED Programme Manager before the indicated deadline. Following submission, applications are considered at a meeting of the Alliance Executive Board, where funding decisions are made. The applications will not be sent for external review.

2.2 **RESEARCH PROPOSAL**

Please use the template provided to complete your research proposal (Section 4.2 of the Pilot application template). **Section 4.2 of the application template should not exceed four standard pages using Arial 10-point font, including figures. References are not included as part of the page restriction. In this section, you should aim to address the content outlined in the table below.**

In your research proposal please include:

- How the proposal will help establish your research in the early detection field
- The novelty of your idea
- The strength of your collaborative team to achieve the endpoints of your proposal
- The downstream translational potential of your idea
- The clinical need addressed by your idea
- The contribution to early detection research should the idea be a success
- Outline any examples of similar and/or competing approaches globally, for the proposed research (e.g. different test to determine the same outcome, different cohorts, etc.).
- If there are commercial collaborators, outline the intellectual engagement and financial investment contributed by the commercial entities, and how this is critical to the proposed research.
### Contents of the research proposal

<table>
<thead>
<tr>
<th>CHALLENGE</th>
<th>State briefly the challenge or hypothesis the proposed project looks to address. Include details of the current state of the art, the unmet need and how the project/collaboration will drive progress in the early detection of cancer.</th>
</tr>
</thead>
</table>
| TEAM COMPOSITION | Please provide information on the composition of the team of applicants and collaborators including:  
- Whether the team or members of the team have published together previously (this is not a requirement).  
- Individual time contributions of those working on the project where possible, stating briefly the added value of the collaboration compared to each researcher working independently.  
- Address how the Alliance environment is critical in supporting the potential of the proposed research and how this Alliance partnership will enable the proposed research compared to Alliance Member Centres conducting the research independently. |
| DEVELOPMENT PLAN AND MILESTONES | Explain clearly how you will address the early detection challenge you have identified. Please provide enough information on how you plan to develop your ideas and build a platform for future research, highlighting the key milestones necessary to achieve this. |
| PROJECT DESCRIPTION | This section is highly important and therefore we suggest you devote a substantial proportion of your research proposal to it.  
- Experimental methods, techniques and analyses that you’ll use to test your hypothesis. Refer to your own published work where you’ve used these methods before or indicate the availability of appropriate expertise. Justify the appropriateness of your experimental design including sample size calculations as appropriate  
- Any available unpublished research findings or methodologies supporting your research proposal (please include these in the text, not as an appendix) |
| EXPECTED OUTPUTS | State the expected outputs of the Pilot Award, including an explanation of why this is important to ACED. Also include a description of your vision for future research proposals which may lead on from this work. |
| REFERENCES | Give full details of any references, including authors, publication year, title and journal name, volume, page numbers. We won’t accept shortened references.  
- Number your references in the order in which they appear in the text, and list them in the Vancouver style (as outlined by the US National Library of Medicine). |
2.3 ADDITIONAL RESEARCH INFORMATION

Please use the provided template to complete the following sections.

Additional information for all proposals

Please list running expenses and provide scientific justification for the associated costs. Costs should be divided and reported separately for each UK and US Member Centre(s) in the local currency of the country in which they are incurred in (e.g. GBP (£) for UK and USD ($) for US). For example, if a cost is associated with research conducted at US Member Centres, it should be reported as Stanford or OHSU-USD ($) amount. Costs associated with research at UK Member Centres, should be reported as Manchester or Cambridge or UCL-GBP (£) amount.

Running Expenses:
- Please list lab consumable costs for each staff member.
- Please list specific costs separately from general consumables.
- Please list any requested equipment under £5k.

Please also list salaries and justification in this section.

Example table:

<table>
<thead>
<tr>
<th>Description</th>
<th>Additional Information</th>
<th>Costs Years 1</th>
<th>Costs Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data storage (Cambridge)</td>
<td>Storing data from RNAseq and DNAseq data and respective public datasets for subsequent analysis</td>
<td>£3200</td>
<td>Cambridge - £3200</td>
</tr>
</tbody>
</table>

STATISTICAL DESIGN AND ANALYSIS PLAN

For each research question as appropriate:
- Describe the statistical analysis used;
- Name the variables and describe the values;
- State the numbers of samples you plan to include in each analysis, describing what you can achieve with this number of samples;
- Include (where appropriate) the associated level of statistical power;
- Suggest any potential limitations;
- Clarify other relevant details (e.g. numbers of events in clinical outcomes, length of follow-up for clinical outcomes).

CELL LINES

Only complete if applicable

Please provide details of any cell lines you will use in your research. These should include:
- Details of how you will maintain good cell culture practices throughout your research project.
- If new cell lines will be introduced to your lab, please give the source will be authenticated when they enter your lab.
- If new cell lines will be generated, please tell us how these will be made available for others to use.
- Justification for the use of any cell lines that have been misidentified (e.g. Chang liver cells).

You can request funding (under running expenses) to support cell line authentication (e.g. screening for contamination by mycoplasma, STR profiling for human cell lines or DNA fingerprinting for non-human cells). You’ll need to validate your cell lines according to the Guidelines for the use of cell lines in biomedical research (doi:10.1038/bjc.2014.166), which should be referenced in any publications resulting from the award.

<table>
<thead>
<tr>
<th>ANIMAL STUDIES</th>
</tr>
</thead>
</table>

### Only complete if applicable

You should complete this section if you are proposing to use animals in your research. You should ensure you are familiar with the relevant NC3Rs guidelines, in particular the Responsibility in the Use of Animals in Bioscience Research document, the ARRIVE Guidelines, and the NC3Rs Guidelines: Primate Accommodation, Care and Use. When completing this section, you should describe how your proposed research adheres to the expectations set out in these guidelines.

#### Animal Costs:
- Please include a full breakdown of the purchase costs and husbandry costs (e.g. per mouse per week).

Please list animal purchase, maintenance and experimental costs separately.

#### Justification of proposed animal studies

Please briefly justify the use of animals by outlining:
- Why animal research is necessary for your award and details of all species you propose to use;
- Why the species/model you have chosen is the most appropriate physiological model to use for the research objective(s);
- If you are developing any new models why this is necessary and how you will ensure that these will be disseminated to the research community more broadly;
- The efforts you will take to minimise animal usage.

For your critical experiments, please provide an outline of your experimental design and power calculations. Where details of specific experiments are not known, you may provide an illustrative example. This should include:

- An overview of the experimental approach summarising; primary and secondary experimental outcomes, number of experimental and control groups, the number of experimental units in each experimental group, the total number of experimental units to be measured and the number of times each unit will be measured, number of independent replications of each experiment and how you plan to minimise experimental bias (e.g. randomisation and blinding) or an explanation of why this would not be appropriate.
- An explanation of how effect sizes have been calculated and a justification of their biological relevance
- The power calculations used to determine your sample size (or a principled explanation of an alternative basis for calculations, justifying why you haven’t used statistical calculations). Explanations based solely in terms of ‘usual practice’ or previously published data will not be considered adequate.
- Details of breeding strategies that will be implemented (if applicable).
• A brief description of your planned statistical analyses in relation to the sample size, and list any statistical advice available.
• You may present this in the form of a table or diagram, if appropriate.

Please note that the NC3Rs website includes a number of useful experimental design resources, including the Experimental Design Assistant (EDA), a free online tool to help optimise experimental design. The EDA can be used to create a visual map of your planned experiments (or a few of them) that may be useful in discussions with your team and statistical advisors. If you use the EDA, you are encouraged to submit the EDA report as a PDF upload.

Please note that applications proposing research on specially protected species (cats, dogs, equines or non-human primates) or pigs must undergo an additional independent peer review by the NC3Rs.

For any animal studies to be performed outside of the UK, we also require a letter to be included with your completed application from the relevant applicant leading this work to confirm that the research proposed will adhere to all relevant local regulatory systems, and also that the welfare standards will be consistent with UK standards.

2.4 ADDITIONAL DOCUMENTS

Letter(s) of Support: If you are listing collaborators external to the Alliance, you must include a brief letter of support as evidence of their commitment to your proposal. Submit any Letters of Support in PDF format, signed, dated and on headed paper alongside your completed application.

3. USEFUL CONTACTS

Once you have read these guidelines, please contact ACED@cancer.org.uk if you have any questions. Your local programme manager can also provide information related to questions for your specific location.

<table>
<thead>
<tr>
<th>Affiliation</th>
<th>Name</th>
<th>Role</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Research UK</td>
<td>Karolin Kroese</td>
<td>ACED Programme Manager</td>
<td><a href="mailto:Karolin.Kroese@cancer.org.uk">Karolin.Kroese@cancer.org.uk</a></td>
</tr>
<tr>
<td>Cambridge</td>
<td>Wendy Alderton</td>
<td>Programme Manager</td>
<td><a href="mailto:wa266@cam.ac.uk">wa266@cam.ac.uk</a></td>
</tr>
<tr>
<td>University College</td>
<td>Daniel Kelberman</td>
<td>Programme Manager</td>
<td><a href="mailto:d.kelberman@ucl.ac.uk">d.kelberman@ucl.ac.uk</a></td>
</tr>
<tr>
<td>London</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OHSU</td>
<td>Erin Watson</td>
<td>Programme Manager</td>
<td><a href="mailto:Watsoner@ohsu.edu">Watsoner@ohsu.edu</a></td>
</tr>
<tr>
<td>Stanford</td>
<td>Ryan Spitler</td>
<td>Programme Manager</td>
<td><a href="mailto:Rspitler@stanford.edu">Rspitler@stanford.edu</a></td>
</tr>
<tr>
<td>Manchester</td>
<td>Martin Bone</td>
<td>Programme Manager</td>
<td><a href="mailto:Martin.Bone@manchester.ac.uk">Martin.Bone@manchester.ac.uk</a></td>
</tr>
</tbody>
</table>